Delaney Dennis R Cellectis S.A. Transaction History
Delaney Dennis R
- $199 Million
- Q3 2025
A detailed history of Delaney Dennis R transactions in Cellectis S.A. stock. As of the latest transaction made, Delaney Dennis R holds 24,000 shares of CLLS stock, worth $94,560. This represents 0.03% of its overall portfolio holdings.
Number of Shares
24,000Holding current value
$94,560% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding CLLS
# of Institutions
32Shares Held
9.73MCall Options Held
52.7KPut Options Held
0-
Long Focus Capital Management, LLC San Juan, PR4.12MShares$16.2 Million0.43% of portfolio
-
B Group, Inc. Dallas, TX3.28MShares$12.9 Million6.88% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$5.67 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$893,8870.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il222KShares$874,5180.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $179M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...